PDF(Pubmed)
Abstract：
Prolyl 4-hydroxylases (P4Hs) are a family of key modifying enzymes in collagen synthesis. P4Hs have been confirmed to be closely associated with tumor occurrence and development. However, the expression of P4Hs in head and neck cancer (HNSC) as well as its relationship with prognosis and tumor immunity infiltration has not yet been analyzed. We investigated the transcriptional expression, survival data, and immune infiltration of P4Hs in patients with HNSC from multiple databases. P4H1-3 expression was significantly higher in HNSC tumor tissues than in normal tissues. Moreover, P4HA1 and P4HA2 were associated with tumor stage, patient prognosis, and immune cell infiltration. P4HA3 was related to patient prognosis and immune cell infiltration. Correlation experiments confirmed that P4HA1 may serve as a prognosis biomarker and plays a role in the progression of nasopharyngeal carcinoma. These findings suggest that P4HA1-3 may be a novel biomarker for the prognosis and treatment of HNSC, which is expected to support the development of new therapies for patients with head and neck tumors and improve patient outcomes.
摘要：
脯氨酸4-羟化酶（P4Hs）是胶原蛋白合成中的关键修饰酶家族。P4Hs已被证实与肿瘤的发生发展密切相关。然而,P4Hs在头颈部恶性肿瘤(HNSC)中的表达及其与预后和肿瘤免疫浸润的关系尚未被分析。我们研究了转录表达，生存数据，来自多个数据库的HNSC患者中P4Hs的免疫浸润。P4H1-3在HNSC肿瘤组织中的表达明显高于正常组织。此外，P4HA1和P4HA2与肿瘤分期相关，患者预后,和免疫细胞浸润。P4HA3与患者预后及免疫细胞浸润有关。相关实验证实，P4HA1可能作为预后标志物，在鼻咽癌的进展中发挥作用。这些结果表明，P4HA1-3可能是HNSC预后和治疗的新生物标志物。有望支持开发头颈部肿瘤患者的新疗法，并改善患者的预后。
